Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Receivables (2021 - 2025)

Rxo (RXO) has disclosed Receivables for 5 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 0.64% year-over-year to $1.3 billion, compared with a TTM value of $1.3 billion through Dec 2025, up 0.64%, and an annual FY2025 reading of $1.3 billion, up 0.64% over the prior year.
  • Receivables was $1.3 billion for Q4 2025 at Rxo, up from $1.1 billion in the prior quarter.
  • Across five years, Receivables topped out at $1.3 billion in Q4 2025 and bottomed at $716.0 million in Q1 2024.
  • Average Receivables over 5 years is $965.1 million, with a median of $1.0 billion recorded in 2022.
  • The sharpest move saw Receivables decreased 22.62% in 2023, then skyrocketed 64.99% in 2024.
  • Year by year, Receivables stood at $1.0 billion in 2021, then fell by 11.76% to $900.0 million in 2022, then decreased by 16.22% to $754.0 million in 2023, then surged by 64.99% to $1.2 billion in 2024, then rose by 0.64% to $1.3 billion in 2025.
  • Business Quant data shows Receivables for RXO at $1.3 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.1 billion in Q2 2025.